SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of its 3D-printed WaveForm TO (TLIF Oblique) Interbody System.

WaveForm TO was designed for both PLIF (posterior lumbar interbody fusion) and TLIF (transforaminal lumbar interbody fusion) procedures. The system accommodates both direct impact insertion and insert-and-rotate techniques. With a comprehensive set of decompression, disc preparation, and implant insertion instruments that are compatible with the NanoMetalene-based Reef TO system, WaveForm TO provides a versatile lumbar interbody solution for surgeons.

“It remains essential to have interbody implants that cumulatively participate in the index biologic fusion response – always advancing the goal of stable osseous union,” said Dr. Erik Westerlund of Jackson Hughston Memorial Hospital in Alabama. “In this context, Waveform TO represents a uniquely-optimized porous titanium TLIF interbody solution.  This refined design incorporates a 3D-printed open gyroid architecture that maintains implant strength while simultaneously providing a favorable fusion environment.”

WaveForm interbody devices offer the next level of 3D-printed architectural innovation, balancing key geometric and manufacturing advancements without compromising clinical requirements. WaveForm TO utilizes innovative WaveForm technology to deliver a highly porous and yet robust interbody solution, with a design intended to optimize subsidence resistance, implant stiffness, and orthobiologics packability, while maintaining radiographic visualization during intraoperative and postoperative imaging.

“WaveForm TO is our first 3D Interbody to commercially launch, with more launches planned before the end of this year,” said Dennis Cirino, Senior Vice President of Global Spinal Systems. “Designed for strength, radiolucency, and an unparalleled ability to pack orthobiologics due to its innovative design.  WaveForm TO is a comprehensive, intuitive, and reliable system capable of addressing multiple patient pathologies. With this launch we have an opportunity to address an additional $500 million market opportunity with this best-in-class technology.”

Source: Company Press Release